ERIC M.
- Country
- France
- Department
- Neurology
Research Overview
- Efficacy and Safety of Remibrutinib in Patients with Secondary Progressive Multiple Sclerosis: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study
- Tenecteplase plus Thrombectomy versus Thrombectomy Alone in Patients with Large Core Ischemic Stroke: A Multicentre Randomized Controlled Trial
- TRIO: A prospective randomized Trial of non-inferiority comparing RItuximab versus Ocrelizumab in relapsing-remitting multiple sclerosis.
Data & Insights
Has run more than one trial at 195 of 385 partner sites.
Specializations
Multiple Sclerosis Research
This investigator specializes in evaluating therapeutic approaches for multiple sclerosis (MS), with particular focus on relapsing-remitting MS and primary progressive MS.
- Novel Treatment Evaluations
- Disease-Modifying Therapies
- Long-term Treatment Outcomes
Their research encompasses various therapeutic agents including BTK inhibitors and monoclonal antibodies for MS treatment.
Treatment Innovation
The investigator focuses on comparing the efficacy of different therapeutic approaches in neurological conditions, particularly examining innovative treatment schedules and administration protocols.
- Comparative Treatment Studies
- Treatment Optimization
- Drug Administration Protocols
Their work includes evaluation of treatment discontinuation strategies and long-term safety assessments.
Cardiovascular Research
The investigator extends their expertise to cardiovascular conditions and cerebrovascular disorders, investigating preventive treatments for major vascular events.
- Stroke Prevention
- Vascular Event Management
- Atherosclerosis Treatment
Their research includes studies on therapeutic interventions for reducing recurrent vascular events.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.